Drug Profile
Research programme: CtlP gene - Myriad Pharmaceuticals
Alternative Names: CtlP gene research programme - Myriad GeneticsLatest Information Update: 10 Aug 2007
Price :
$50
*
At a glance
- Originator Myriad Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Aug 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 07 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 01 Jun 2000 Myriad Genetics has received a US patent for this research programme